General Oncology

Executive Summary

General Oncology is a private biopharmaceutical company developing multi-modal small molecule therapies to overcome tumor drug resistance and reduce chronic toxicity in metastatic cancers. Founded in 2017 and headquartered in New York with a lab in Newton, Massachusetts, the company's lead candidate, GO-4305C, targets stage IV pancreatic cancer and has shown promising early clinical results. The company is currently in Phase 1 development, focusing on validating its platform technology that addresses key resistance mechanisms. With a lean operation and a strong scientific foundation, General Oncology aims to address significant unmet needs in hard-to-treat cancers. The upcoming catalysts, including Phase 1 data readouts and potential partnering discussions, will be critical for advancing its pipeline and securing additional funding. The company's novel approach and early clinical data position it as an intriguing player in oncology, though the inherent risks of early-stage drug development remain. Conviction score reflects the potential but acknowledges the need for further clinical validation.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 dose-escalation data update for GO-4305C in pancreatic cancer40% success
• Q1 2027Initiation of Phase 1b expansion cohort for GO-4305C60% success
• Q4 2026Potential strategic partnership or Series B financing30% success